GenVec Financing Sinks Shares: BioBuzz
GAITHERSBURG, Md. (TheStreet) -- Shares of GenVec (GNVC) are down 23% Wednesday after the tiny drug maker said it had sold 14 million shares of stock and another 4.2 million warrants, raising net proceeds of $26.2 million.
The GenVec offering of units consisting of stock and warrants, priced at $2 per unit, comes predictably after a run in GenVec's stock price, which has essentially doubled since December. The stock closed Tuesday at $2.47. In recent trading, shares were down to $1.88.
Biotech, especially small-cap biotechs, do one thing exceptionally well -- raise money. Investors take note.
"Dilution is the name of the game after big runs in the market, especially in a market place where all small bios are raising cash as a group," says JohnWelshPhd, a savvy trader, including of small-cap biotech stocks, who I follow on Twitter.When news of the GenVec offering broke, JohnWelshPhd tweeted, "Surprise factor zero." So true. Now, the $26 million dollar question is whether Wednesday's financing implies anything about the upcoming interim analysis of the phase III study of TNFerade in pancreatic cancer. Is GenVec simply being opportunistic about raising money ahead of this important, potentially stock-moving event? Or, is the company fearful that the TNFerade results will be negative, so it's getting the money now while it can? No one but GenVec knows the answer, of course, and executives aren't about to tell us. When Cell Therapeutics (CTIC) raised money a couple of weeks ago, just before the FDA advisory panel for its lymphoma drug pixantrone, I wrote that that it presaged bad things for the drug.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV